Helicobacter pylori infection
Conditions
Interventions
Dual therapy group:Vonola fumarate raw tablets 20 mg/time, 2 times/day + Amoxicillin Capsules 500 mg/time, 3 times/d
course of treatment 7d
Quadruple therapy group:Omeprazole enteric-coated capsules 20 mg/time, 2 times/d + colloidal bismuth pectin capsules 200 mg/time, 2 times/d + amoxicillin capsules 1000 mg/time, 2 times/d + clarithromy
the course of treatment is 14 days
Sponsors
Qingyuan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Healthy population with positive 13C-urea breath test, aged 18-70 years; 2.Meet the indication of Helicobacter pylori eradication (according to the "fifth National Consensus Report on Helicobacter pylori infection Management").
Exclusion criteria
Exclusion criteria: 1.A history of Hp eradication; 2.History of esophageal or gastric surgery; 3.Patients with peptic ulcer, gastrointestinal bleeding, gastric cancer or gastric MALT lymphoma; 4.Antibiotics, bismuth and traditional Chinese medicine containing antibacterial activity were taken 4 weeks before treatment, and vonorazone, PPI, H2 receptor antagonist and other drugs were taken 2 weeks before treatment; 5.Severe heart, lung, kidney, liver insufficiency, low immunity; 6.Pregnant and lactating patients; 7.People with mental illness or communication disorder; 8.Patients who are allergic to the drugs used in the eradication programme.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the eliminate rate of Hp; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactPeng Tieli
Qingyuan People's Hospital
Outcome results
None listed